Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Dr. Reddy's delivered a record quarter with INR 6,880 crore revenue (+9% YoY) and INR 2,181 crore EBITDA (+30% YoY), driven by strong US generics (up 9% to $384M) and Europe (up 12% to EUR 59M). EBITDA margin expanded to 31.7% despite SG&A investments. India business grew only 2% YoY due to NLEM price cuts and portfolio pruning, but management expects double-digit growth by year-end, supported by ~10 licensing deals for innovative products. US price erosion remains moderate, and the Mayne portfolio integration is on track. Biosimilar rituximab launch in the US is expected in early FY2025. Key risk: FDA observations at the Bachupally biologics facility (9 observations) could delay biosimilar approvals if not resolved timely.
डॉ. रेड्डीज ने इस तिमाही में शानदार प्रदर्शन किया। कंपनी की कुल कमाई 6,880 करोड़ रुपये रही, जो पिछले साल से 9% ज्यादा है। मुनाफा (EBITDA) 2,181 करोड़ रुपये रहा, जो 30% बढ़ा। अमेरिका में जेनेरिक दवाओं की बिक्री 9% बढ़कर 384 मिलियन डॉलर और यूरोप में 12% बढ़कर 59 मिलियन यूरो हुई। कंपनी का मुनाफा मार्जिन 31.7% तक पहुंच गया। भारत में बिक्री सिर्फ 2% बढ़ी, क्योंकि सरकार ने कुछ दवाओं के दाम घटाए और कंपनी ने कमजोर उत्पादों को हटाया। लेकिन कंपनी को उम्मीद है कि साल के अंत तक भारत में दोहरे अंकों में वृद्धि होगी। अमेरिका में दवाओं के दाम गिरने की रफ्तार धीमी है। बायोसिमिलर रीटक्सिमैब अगले साल की शुरुआत में अमेरिका में लॉन्च हो सकता है। लेकिन बचुपल्ली फैक्ट्री में FDA ने 9 खामियां पाई हैं, जिन्हें जल्द ठीक नहीं किया गया तो नई दवाओं की मंजूरी में देरी हो सकती है।
Promises0 met · 1 missedRisks3 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
3 risks
Risk Intelligence
FDA observations at Bachupally biologics facility
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Generics Revenue
$384M
+9% YoY
North America generics revenue grew 9% YoY to $384M, driven by market share expansion and Mayne portfolio integration.
Europe Revenue
EUR 59M
+12% YoY
Europe business grew 12% YoY to EUR 59M, supported by new product launches and tender wins.
India Revenue
INR 1,186 Cr
+2% YoY
India revenue grew 2% YoY; excluding NLEM impact, mid-single-digit growth. Focus portfolio growing double digits.
R&D Spend %
7.9%
flat YoY
R&D spend at 7.9% of sales, driven by clinical trials for biosimilars and differentiated assets.
What Changed vs Last Quarter
NEW
India business to achieve double-digit growth by end of FY2024
Management expects India business to exit FY2024 with double-digit growth, driven by licensing deals and focus portfolio expansion.
NEW
25-30 product launches in US for FY2024
Company is on track to launch 25-30 products in the US this fiscal year, with 4 launched in Q2.
NEW
Biosimilar rituximab launch in US in early FY2025
Rituximab biosimilar submitted in April 2023; pre-approval inspection completed. Launch expected in early FY2025 if regulatory issues resolved.
NEW
SG&A as % of sales to remain around 28-29% for FY2024
CFO indicated SG&A as a percentage of sales will be in the 28-29% range for the full year, despite investments in digitalization and brands.
DROPPED
Long-term EBITDA margin target of ~25%
Management reiterated 25% as the sustainable EBITDA margin level, though near-term will be higher due to lenalidomide.
DROPPED
U.S. growth momentum to continue
Expects sustained strong performance in North America generics, including base business growth and new product launches.
DROPPED
India innovation pipeline to drive top-5 aspiration
Plans to sign tens of licensing deals for innovative products in India, with meaningful revenue contribution from FY2025.
DROPPED
R&D investment in biosimilars to increase
Biosimilar R&D currently ~20% of total R&D; expected to grow progressively with pipeline advancement.
NEW RISK
FDA observations at Bachupally biologics facility
US FDA pre-approval inspection resulted in 9 observations. Management believes they are addressable but could delay biosimilar approvals if not resolved timely.
NEW RISK
India business growth trajectory uncertainty
Despite guidance for double-digit growth by year-end, India business has been range-bound for several quarters. Analyst questioned the timeline for material step-up.
RISK GONE
Lenalidomide revenue dependency
Significant portion of U.S. growth attributed to lenalidomide; agreement ends January 2026, creating uncertainty beyond.
RISK GONE
Russia market volatility
Russia business grew 77% but on a low base; currency and geopolitical risks remain high.
RISK GONE
India innovation execution risk
Top-5 aspiration relies on signing and commercializing multiple innovative products; timeline and uptake uncertain.
Fast read
Guidance and risk preview
Management expects India business to exit FY2024 with double-digit growth, driven by licensing deals and focus portfolio expansion.
US FDA pre-approval inspection resulted in 9 observations.
View Risks →